RPS6KA1 and acute myeloid leukemia: We validated RPS6KA1 inhibition by BI-D1870 as potential combination partner for venetoclax/azacitidine and demonstrated that inhibition of proliferation and colony growth of AML cells was strongly enhanced under triple therapy.